Advertisement
AMGN vs LLY
Which Stock Would AI Choose? Amgen (AMGN) vs. Eli Lilly (LLY) Stock Comparison
Key Takeaways
- AMGN reported first-quarter 2026 revenues of $8.6 billion, reflecting 6% year-over-year growth supported by 16 products with double-digit sales increases.
- LLY has demonstrated stronger recent momentum, with its shares reaching multiple all-time highs in early July 2026 amid sustained demand for its key therapies.
- Both companies operate in the biotechnology and pharmaceuticals sector, yet LLY benefits from dominant positioning in high-growth areas such as diabetes and obesity treatments.
- AMGN maintains a more diversified portfolio across oncology, cardiovascular, and inflammation, providing relative stability during market volatility.
- Valuation metrics show LLY trading at a premium consistent with its elevated growth trajectory compared to AMGN.
- Analyst sentiment remains constructive for both stocks, with ongoing adjustments to price targets reflecting evolving earnings expectations.
Introduction
This comparison examines AMGN and LLY, two prominent biotechnology companies with distinct yet overlapping portfolios in therapeutic areas including inflammation, oncology, and metabolic diseases. Traders and investors focused on sector rotation, relative value, and momentum shifts within healthcare may find this analysis relevant for assessing positioning in the current market environment. The review draws on recent financial results, price behavior, and analyst commentary to highlight observable differences in performance and risk profiles.
AMGN Overview and Recent Performance
Amgen Inc. develops and commercializes therapies across multiple therapeutic areas, with key products including Repatha for cardiovascular health and TEPEZZA for thyroid eye disease. In recent market activity, the stock has traded near $368, delivering a year-to-date return of approximately 14% through early July 2026. First-quarter 2026 results showed total revenues rising 6% to $8.6 billion, driven by volume growth across 16 brands. Sentiment has been influenced by steady product execution alongside analyst price target revisions, some upward and others reflecting valuation considerations amid broader sector dynamics.
LLY Overview and Recent Performance
Eli Lilly and Company focuses on innovative medicines, particularly in diabetes, obesity, and oncology. The stock has exhibited robust recent performance, attaining all-time highs near $1,249 in early July 2026 before settling around $1,220. Strong demand for its metabolic therapies has supported elevated growth rates, with the company reporting substantial revenue increases in prior quarters. Market sentiment remains positive, bolstered by analyst upgrades and the company’s expanding commercial reach, contributing to outperformance relative to broader indices in recent weeks.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of AI-powered trading bots from hundreds available that trade thousands of different tickers. Only the best and most suitable for current market conditions earn placement in this section. These bots feature varied trading styles, strategies, timeframes, performance statistics, and ticker sets. Available options include ranges of historical win rates, profit factors, and drawdown metrics that appeal to diverse investor preferences. Review the platform for detailed bot profiles and performance data.
Head-to-Head Comparison
AMGN and LLY differ markedly in scale and growth drivers. LLY maintains a concentrated exposure to high-growth metabolic therapies, supporting faster revenue expansion and higher valuation multiples. In contrast, AMGN offers broader diversification across established franchises, which can provide greater resilience during periods of sector-specific pressure. Recent momentum favors LLY, evidenced by its outsized stock gains and all-time highs, while AMGN has delivered more moderate returns amid steady but less explosive product performance. Risk factors for LLY include elevated valuation sensitivity to clinical or regulatory developments, whereas AMGN contends with competition in certain legacy areas. Sector exposure remains similar, yet market sentiment has tilted toward LLY’s growth narrative in recent activity.
Tickeron AI Verdict
Based on observable factors including trend consistency, relative momentum, and positioning around key catalysts, Tickeron’s AI models may currently assign a higher probability of favorable near-term performance to LLY. This assessment reflects the stock’s stronger recent price behavior and sustained commercial tailwinds compared with AMGN’s more measured trajectory. Outcomes remain subject to evolving market conditions and company-specific developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsTo compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and LLY is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green whileLLY’s FA Score has 3 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- LLY’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 6 TA indicator(s) are bullish while LLY’s TA Score has 3 bullish TA indicator(s).
- AMGN’s TA Score: 6 bullish, 4 bearish.
- LLY’s TA Score: 3 bullish, 5 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а -2.88% price change this week, while LLY (@Pharmaceuticals: Major) price change was -2.09% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.40%. For the same industry, the average monthly price growth was +12.67%, and the average quarterly price growth was +6.87%.
Reported Earning Dates
AMGN is expected to report earnings on Aug 04, 2026.
LLY is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-2.40% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | LLY | AMGN / LLY | |
| Capitalization | 196B | 1.06T | 18% |
| EBITDA | 16.7B | 36.2B | 46% |
| Gain YTD | 12.637 | 10.974 | 115% |
| P/E Ratio | 25.29 | 42.22 | 60% |
| Revenue | 37.2B | 72.2B | 52% |
| Total Cash | 12B | 5.28B | 227% |
| Total Debt | 57.3B | 43.4B | 132% |
AMGN | LLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 71 Overvalued | |
PROFIT vs RISK RATING 1..100 | 21 | 11 | |
SMR RATING 1..100 | 12 | 12 | |
PRICE GROWTH RATING 1..100 | 30 | 12 | |
P/E GROWTH RATING 1..100 | 58 | 84 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (9) in the Biotechnology industry is somewhat better than the same rating for LLY (71) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is in the same range as AMGN (21) in the Biotechnology industry. This means that LLY’s stock grew similarly to AMGN’s over the last 12 months.
LLY's SMR Rating (12) in the Pharmaceuticals Major industry is in the same range as AMGN (12) in the Biotechnology industry. This means that LLY’s stock grew similarly to AMGN’s over the last 12 months.
LLY's Price Growth Rating (12) in the Pharmaceuticals Major industry is in the same range as AMGN (30) in the Biotechnology industry. This means that LLY’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's P/E Growth Rating (58) in the Biotechnology industry is in the same range as LLY (84) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to LLY’s over the last 12 months.
| AMGN | LLY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 64% | 2 days ago 71% |
| Stochastic ODDS (%) | 2 days ago 47% | 2 days ago 62% |
| Momentum ODDS (%) | 2 days ago 58% | 2 days ago 64% |
| MACD ODDS (%) | 2 days ago 65% | 2 days ago 72% |
| TrendWeek ODDS (%) | 2 days ago 53% | 2 days ago 60% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 68% |
| Advances ODDS (%) | 16 days ago 57% | 13 days ago 70% |
| Declines ODDS (%) | 2 days ago 52% | 11 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 50% | 2 days ago 51% |
| Aroon ODDS (%) | 2 days ago 53% | 2 days ago 71% |
Advertisement
AMGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with BIIB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | -0.06% | ||
| BIIB - AMGN | 62% Loosely correlated | +0.12% | ||
| PFE - AMGN | 53% Loosely correlated | -0.33% | ||
| GILD - AMGN | 52% Loosely correlated | -3.72% | ||
| SNY - AMGN | 39% Loosely correlated | -0.91% | ||
| OGN - AMGN | 22% Poorly correlated | +0.22% | ||
More | ||||
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with AMGN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then AMGN could also see price increases.